The FDA has approved updated labeling for Sublocade (buprenorphine extended-release) injection to include a rapid induction protocol and alternative injection sites.

SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use [package insert]. North Chesterfield, VA: Indivior PLC; 2025. Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM.

(RTTNews) - Indivior PLC (INDV) announced the FDA has approved label changes for SUBLOCADE including a rapid initiation protocol and alternative injection sites. Healthcare providers can now ...

New data show that rapid initiation with once-monthly Sublocade significantly improved treatment retention vs. standard initiation among patients with opioid use disorder, according to a press ...

Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.

Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly.

--Indivior PLC, a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration has approved label changes for SUBLOCADE ® including a rapid initiation protocol ...

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also ...

Alternative Injection Sites: SUBLOCADE can now be administered subcutaneously in the abdomen, thigh, buttock, or back of the upper arm, offering patients and healthcare providers increased ...